摘要
第2型鈉－葡萄糖共同運輸蛋白（sodium glucose cotransporter 2, SGLT2）抑制劑如dapagliflozin以及empagliflozin等，在很多大型試驗中表現出可減少糖尿病病患或非糖尿病病患心衰竭住院發生率、心因性死亡發生率、腎臟不良事件發生率，以及可以改善心衰竭的堪薩斯市心肌病變問卷症狀分數。此類糖尿病藥物因為它的心血管益處，目前被建議使用在心衰竭的病患。
參考文獻
Thomas M Maddox, James L Januzzi Jr, Larry A Allen, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021;77:772-810.
David M. Williams, Marc Evans. Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver? Diabetes Ther 2020:2207-19.
Qingchun Zeng, Qing Zhou, Weitao Liu, et al. Mechanisms and Perspectives of
Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure. Front Cardiovasc Med 2021;8:636152.
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction, N Engl J Med 2019;381:1995-2008
Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomeswith Empagliflozin in Heart Failure. N Engl J Med 2020;383:1413-24.